Previous close | 158,100.00 |
Open | 164,500.00 |
Bid | 176,200.00 x 0 |
Ask | 176,300.00 x 0 |
Day's range | 157,000.00 - 180,900.00 |
52-week range | 134,700.00 - 212,000.00 |
Volume | |
Avg. volume | 214,327 |
Market cap | 9.606T |
Beta (5Y monthly) | 0.81 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 12 Aug 2024 - 16 Aug 2024 |
Forward dividend & yield | 5,000.00 (2.84%) |
Ex-dividend date | 29 Mar 2024 |
1y target est | 246,818.00 |
SK E&S has collaborated with global partners to establish foundation for the domestic low-carbon hydrogen* industry, with support from local government. They plan to mass-produce low-carbon hydrogen, leading the early establishment of the domestic hydrogen ecosystem and contributing to global carbon neutrality.
SK pharmteco will participate at the CPHI 2023 in Barcelona and prepare a dedicated booth at the event. As a multi-modality CDMO with expertise in small molecule active pharmaceutical ingredients (APIs) and biopharmaceuticals, SK pharmteco aims to present its business competitiveness and actively pursue business opportunities.
As the date for the selection of the host country for the World Expo 2030 has been announced for November 28, Busan, the second-largest city in Republic of Korea after Seoul, wishes to reaffirm its desire to host this unique event more than ever. Korea aims to turn the World Expo 2030 Busan into a significant milestone that shifts the paradigm of the international community from competition to solidarity by offering unique experiences for global citizens to share and explore various ideas, rathe